Jacobsen, Annette V. http://orcid.org/0000-0003-0252-7685
Pierotti, Catia L.
Lowes, Kym N.
Au, Amanda E.
Zhang, Ying
Etemadi, Nima http://orcid.org/0000-0002-7137-1373
Fitzgibbon, Cheree
Kersten, Wilhelmus J. A.
Samson, André L. http://orcid.org/0000-0002-0637-2716
van Delft, Mark F. http://orcid.org/0000-0002-3866-4318
Huang, David C. S. http://orcid.org/0000-0002-3101-4873
Sabroux, Hélène Jousset
Lessene, Guillaume http://orcid.org/0000-0002-1193-8147
Silke, John http://orcid.org/0000-0002-7611-5774
Murphy, James M. http://orcid.org/0000-0003-0195-3949
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1156024, 1117089, 1067289, 1058190, 1107149, 1105754, 1172929, 1124735, 1124737, 9000719)
Article History
Received: 24 August 2020
Revised: 14 March 2022
Accepted: 16 March 2022
First Online: 1 April 2022
Competing interests
: CLP, KNL, AEA, YZ, NE, CF, WJAK, ALS, HJS, GL, JS and JMM contribute, or have contributed, to a project developing necroptosis inhibitors in collaboration with Anaxis Pty Ltd. AVJ, MFvD, and DCSH declare no conflicts of interest.
: Mouse dermal fibroblasts were prepared using procedures approved by and conducted in accordance with the Animal Ethics Committee of the Walter and Eliza Hall Institute, Australia.